Bruker (NASDAQ:BRKR) Given New $60.00 Price Target at Wells Fargo & Company

Bruker (NASDAQ:BRKR - Get Free Report) had its price target lowered by investment analysts at Wells Fargo & Company from $75.00 to $60.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an "overweight" rating on the medical research company's stock. Wells Fargo & Company's target price points to a potential upside of 62.34% from the stock's current price.

A number of other research firms have also weighed in on BRKR. Barclays reduced their price objective on Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Guggenheim reiterated a "buy" rating on shares of Bruker in a research note on Monday, February 24th. Stifel Nicolaus cut their price objective on shares of Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a report on Friday, February 14th. Finally, Citigroup cut their price target on Bruker from $75.00 to $50.00 and set a "buy" rating for the company in a research note on Monday, April 7th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Bruker presently has an average rating of "Moderate Buy" and a consensus price target of $65.00.

Bruker Stock Performance

Shares of NASDAQ BRKR traded up $0.98 during mid-day trading on Thursday, hitting $36.96. The stock had a trading volume of 2,289,626 shares, compared to its average volume of 1,503,558. The company has a 50 day moving average of $44.21 and a two-hundred day moving average of $53.36. Bruker has a twelve month low of $34.10 and a twelve month high of $83.32. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The firm has a market cap of $5.60 billion, a PE ratio of 48.63, a PEG ratio of 2.16 and a beta of 1.18.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Research analysts predict that Bruker will post 2.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Barclays PLC increased its holdings in shares of Bruker by 36.5% in the third quarter. Barclays PLC now owns 55,685 shares of the medical research company's stock valued at $3,847,000 after purchasing an additional 14,888 shares during the last quarter. Sanctuary Advisors LLC increased its stake in shares of Bruker by 95.8% in the 3rd quarter. Sanctuary Advisors LLC now owns 9,089 shares of the medical research company's stock worth $628,000 after acquiring an additional 4,447 shares during the last quarter. Retirement Systems of Alabama raised its holdings in shares of Bruker by 11.7% during the 3rd quarter. Retirement Systems of Alabama now owns 134,254 shares of the medical research company's stock worth $9,272,000 after acquiring an additional 14,069 shares during the period. GAMMA Investing LLC boosted its position in shares of Bruker by 47.5% during the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock valued at $75,000 after acquiring an additional 412 shares during the last quarter. Finally, Everence Capital Management Inc. acquired a new stake in Bruker during the fourth quarter worth about $251,000. 79.52% of the stock is owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.